NCT02292472View on ClinicalTrials.gov

Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

October 6, 2014

Primary Completion Date

May 24, 2015

Study Completion Date

August 24, 2015

Conditions
Hypertrophy of Masseter Muscle
Interventions
DRUG

Botulinum Toxin Type A

Inject intramuscularly once in visit 2

DRUG

Placebos

Inject intramuscularly once in visit 2

Trial Locations (1)

Unknown

Chungang university hospital, Seoul

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT02292472 - Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy | Biotech Hunter | Biotech Hunter